Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN
Clin. transl. oncol. (Print)
; 12(4): 310-314, abr. 2010. ilus
Article
in English
| IBECS
| ID: ibc-124076
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided (AU)
RESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Quinazolines
/
Brain Neoplasms
/
Glioblastoma
/
PTEN Phosphohydrolase
/
ErbB Receptors
/
Antineoplastic Agents
Limits:
Female
/
Humans
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2010
Document type:
Article
Institution/Affiliation country:
Hospital Universitario Clínico San Carlos/Spain